343 related articles for article (PubMed ID: 30076454)
1. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
[TBL] [Abstract][Full Text] [Related]
2. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
[TBL] [Abstract][Full Text] [Related]
3. Preventing future fractures: effectiveness of an orthogeriatric fracture liaison service compared to an outpatient fracture liaison service and the standard management in patients with hip fracture.
Naranjo A; Fernández-Conde S; Ojeda S; Torres-Hernández L; Hernández-Carballo C; Bernardos I; Rodríguez S; Laynez P
Arch Osteoporos; 2017 Dec; 12(1):112. PubMed ID: 29230540
[TBL] [Abstract][Full Text] [Related]
4. Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial.
McAlister FA; Ye C; Beaupre LA; Rowe BH; Johnson JA; Bellerose D; Hassan I; Majumdar SR
Osteoporos Int; 2019 Jan; 30(1):127-134. PubMed ID: 30232538
[TBL] [Abstract][Full Text] [Related]
5. Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates.
Ojeda-Bruno S; Naranjo A; Francisco-Hernández F; Erausquin C; Rúa-Figueroa I; Quevedo JC; Rodríguez-Lozano C
Osteoporos Int; 2011 Jun; 22(6):1821-8. PubMed ID: 20924747
[TBL] [Abstract][Full Text] [Related]
6. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
Wang Z; Ward MM; Chan L; Bhattacharyya T
Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
[TBL] [Abstract][Full Text] [Related]
7. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
[TBL] [Abstract][Full Text] [Related]
8. Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study.
Shah A; Prieto-Alhambra D; Hawley S; Delmestri A; Lippett J; Cooper C; Judge A; Javaid MK;
Osteoporos Int; 2017 Jan; 28(1):169-178. PubMed ID: 27812809
[TBL] [Abstract][Full Text] [Related]
9. Oral bisphosphonates are associated with reduced mortality after hip fracture.
Beaupre LA; Morrish DW; Hanley DA; Maksymowych WP; Bell NR; Juby AG; Majumdar SR
Osteoporos Int; 2011 Mar; 22(3):983-91. PubMed ID: 21052642
[TBL] [Abstract][Full Text] [Related]
10. Incidence of second hip fracture and compliant use of bisphosphonate.
Lee YK; Ha YC; Yoon BH; Koo KH
Osteoporos Int; 2013 Jul; 24(7):2099-104. PubMed ID: 23247329
[TBL] [Abstract][Full Text] [Related]
11. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
12. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
Olsen KR; Hansen C; Abrahamsen B
Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
[TBL] [Abstract][Full Text] [Related]
13. Impact of interactive voice response technology on primary adherence to bisphosphonate therapy: a randomized controlled trial.
Cizmic AD; Heilmann RM; Milchak JL; Riggs CS; Billups SJ
Osteoporos Int; 2015 Aug; 26(8):2131-6. PubMed ID: 25956282
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate use and subsequent hip fracture in South Korea.
Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
[TBL] [Abstract][Full Text] [Related]
15. Primary non-adherence to bisphosphonates in an integrated healthcare setting.
Reynolds K; Muntner P; Cheetham TC; Harrison TN; Morisky DE; Silverman S; Gold DT; Vansomphone SS; Wei R; O'Malley CD
Osteoporos Int; 2013 Sep; 24(9):2509-17. PubMed ID: 23595561
[TBL] [Abstract][Full Text] [Related]
16. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
Ganda K; Schaffer A; Pearson S; Seibel MJ
Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
[TBL] [Abstract][Full Text] [Related]
17. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
18. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
Modi A; Tang J; Sen S; Díez-Pérez A
Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
[TBL] [Abstract][Full Text] [Related]
19. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.
Desai RJ; Mahesri M; Abdia Y; Barberio J; Tong A; Zhang D; Mavros P; Kim SC; Franklin JM
JAMA Netw Open; 2018 Jul; 1(3):e180826. PubMed ID: 30646034
[TBL] [Abstract][Full Text] [Related]
20. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study.
Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R
Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
